APA (7th ed.) Citation

KT, M., KY, I., V, I., RM, M., CFD, S., JC, B., . . . VC, C. (2025). Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals. Revista do Instituto de Medicina Tropical de Sao Paulo, 67, e2. https://doi.org/10.1590/S1678-9946202567002

Chicago Style (17th ed.) Citation

KT, Miyaji, et al. "Safety of Two-dose Schedule of COVID-19 Adsorbed Inactivated Vaccine (CoronaVac; Sinovac/Butantan) and Heterologous Additional Doses of MRNA BNT162b2 (Pfizer/BioNTech) in Immunocompromised and Immunocompetent Individuals." Revista Do Instituto De Medicina Tropical De Sao Paulo 67 (2025): e2. https://doi.org/10.1590/S1678-9946202567002.

MLA (9th ed.) Citation

KT, Miyaji, et al. "Safety of Two-dose Schedule of COVID-19 Adsorbed Inactivated Vaccine (CoronaVac; Sinovac/Butantan) and Heterologous Additional Doses of MRNA BNT162b2 (Pfizer/BioNTech) in Immunocompromised and Immunocompetent Individuals." Revista Do Instituto De Medicina Tropical De Sao Paulo, vol. 67, 2025, p. e2, https://doi.org/10.1590/S1678-9946202567002.